BCAX
NASDAQ · Biotechnology
Bicara Therapeutics Inc
$18.22
-0.17 (-0.92%)
Financial Highlights (FY 2025)
Revenue
181.36M
Net Income
-39,755,825
Gross Margin
42.6%
Profit Margin
-21.9%
Rev Growth
+5.9%
D/E Ratio
0.58
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 42.6% | 42.6% | 42.6% |
| Operating Margin | -24.5% | -23.9% | -25.6% |
| Profit Margin | -21.9% | -22.5% | -20.2% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 181.36M | 184.14M | 159.71M |
| Gross Profit | 77.18M | 78.36M | 67.96M |
| Operating Income | -44,403,132 | -44,060,984 | -40,892,853 |
| Net Income | -39,755,825 | -41,476,631 | -32,201,263 |
| Gross Margin | 42.6% | 42.6% | 42.6% |
| Operating Margin | -24.5% | -23.9% | -25.6% |
| Profit Margin | -21.9% | -22.5% | -20.2% |
| Rev Growth | +5.9% | -5.2% | -5.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 315.34M | 288.83M | 313.49M |
| Total Equity | 546.31M | 514.68M | 569.60M |
| D/E Ratio | 0.58 | 0.56 | 0.55 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -52,674,751 | -54,395,580 | -46,526,832 |
| Free Cash Flow | -41,149,249 | -44,589,211 | -37,987,097 |